Asked by: Yvonne Fovargue (Labour - Makerfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what his planned timetable is for the publication of responses to the consultation entitled Advancing our health: prevention in the 2020s, published on 22 July 2019.
Answered by Neil O'Brien
We have no current plans to publish a summary of the responses to the consultation ‘Advancing our health: prevention in the 2020s’ and there are no plans to publish next steps.
Asked by: Yvonne Fovargue (Labour - Makerfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many severe asthma patients were refused biologic treatment in the last 12 months.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
The information on the proportion of severe asthma patients prescribed a biologic is not held in the format requested. However, 3,396 patients commenced a new biologic therapy for severe asthma in the last year. All those patients considered to benefit from a biologic treatment by a specialist severe asthma team will have received the treatment.
Asked by: Yvonne Fovargue (Labour - Makerfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what proportion of severe asthma patients have been prescribed a biologic in the last 12 months.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
The information on the proportion of severe asthma patients prescribed a biologic is not held in the format requested. However, 3,396 patients commenced a new biologic therapy for severe asthma in the last year. All those patients considered to benefit from a biologic treatment by a specialist severe asthma team will have received the treatment.
Asked by: Yvonne Fovargue (Labour - Makerfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many and what proportion of rheumatoid arthritis patients received a biologic in the last 12 months.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
This information is not collected in the format requested.
Asked by: Yvonne Fovargue (Labour - Makerfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many rheumatoid arthritis patients received a biologic in each of the last three years.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
This information is not collected in the format requested.
Asked by: Yvonne Fovargue (Labour - Makerfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, If he will include metrics on the uptake of biologics for severe asthma in the update to the NHS Long Term Plan.
Answered by Gillian Keegan - Secretary of State for Education
The Department and NHS England are currently reviewing delivery of the commitments made in the NHS Long Term Plan, including those relating to respiratory outcomes. The update to the NHS Long Term Plan will be published later this year.
There are no current plans to include metrics measuring uptake of biologics in the NHS Long Term Plan update. However, pathways to biologic therapy are being streamlined, including through the Accelerated Access Collaborative’s work to improve the identification of patients in primary and secondary care settings for referrals to assess suitability to receive biologic treatment.
Asked by: Yvonne Fovargue (Labour - Makerfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he plans to amend the respiratory outcomes section in the update of the NHS Long Term Plan.
Answered by Gillian Keegan - Secretary of State for Education
The Department and NHS England are currently reviewing delivery of the commitments made in the NHS Long Term Plan, including those relating to respiratory outcomes. The update to the NHS Long Term Plan will be published later this year.
There are no current plans to include metrics measuring uptake of biologics in the NHS Long Term Plan update. However, pathways to biologic therapy are being streamlined, including through the Accelerated Access Collaborative’s work to improve the identification of patients in primary and secondary care settings for referrals to assess suitability to receive biologic treatment.
Asked by: Yvonne Fovargue (Labour - Makerfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has plans to include measures to promote an increase in treatment reviews of chronic obstructive pulmonary disease patients who are risk of exacerbation within CORE20+5.
Answered by James Morris
There are no plans to do so. However, Core20PLUS5 supports increasing the uptake of COVID-19, flu and pneumonia vaccines to reduce infective exacerbations and potential emergency hospital admissions.
Asked by: Yvonne Fovargue (Labour - Makerfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent estimate he has made of the number of patients who have received all components of the discharge bundle included in the Best Practice Tariff for chronic obstructive pulmonary disease in the last 12 months.
Answered by James Morris
No specific estimate has been made. Compliance with the Best Practice Tariff criteria is measured by the National COPD Audit Programme’s secondary care audit.
Asked by: Yvonne Fovargue (Labour - Makerfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has plans to include incentives within the Quality and Outcomes Framework or Investment and Impact Fund to help ensure that chronic obstructive pulmonary disease (COPD) patients receive a proactive review of their care after a prescription of oral corticosteroid for a COPD exacerbation.
Answered by James Morris
We have no specific plans to do so. However, the Quality and Outcomes Framework and the Investment and Impact Fund are reviewed to ensure alignment with the latest clinical guidance and best practice.